.png?width=2400&height=263&name=Emergent-BioServices_CMYK_Logo-Tagline-Lockup%20(2).png "Emergent BioSolutions CDMO"){kind=logo}
11.30.2023
3 Things Manufacturers Need to Know About the New Annex 1 Revision
In August 2023, long-awaited drug manufacturing regulations took effect with the implementation of the European Commission’s...
10.26.2023
Key Considerations When Partnering with a CDMO for Your Plasma-Derived Therapies
Plasma contains an array of beneficial constituents that, when purified and concentrated, can be administered as medicines to...
06.28.2023
4 Steps for a Smooth Tech Transfer When Working with a CDMO
In our recent article with BioPharma Dive, Emergent's Shelly Buhay, Director of MS&T and Dan Perrin, Director of Manufacturing...
03.22.2023
How to Mitigate Risk for Biologics During Fill/Finish Manufacturing
As more biologics move through research and development, the demand for specialized aseptic fill/finish services has steadily...
11.02.2022
The Demand for Nanoparticles in Drug Formulation is Rising
Demand for nanoparticles in the biopharmaceutical industry is on the rise. Production of these tiny particles, which can protect...
10.04.2022
Focus on Fill and Finish
Kelly Christiansen, vice president & general manager of Emergent CDMO's Rockville drug product manufacturing facility recently...